| 30 Nov 2026 |
bezuclastinibCogent Biosciences, Inc. (COGT) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 22 Dec 2026 |
LorundrostatMineralys Therapeutics Inc. (MLYS) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 22 Dec 2026 |
LorundrostatMineralys Therapeutics Inc. (MLYS) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 30 Dec 2026 |
bezuclastinibCogent Biosciences, Inc. (COGT) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 30 Dec 2026 |
bezuclastinibCogent Biosciences, Inc. (COGT) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 1 Feb 2027 |
MitapivatAgios Pharmaceuticals, Inc. (AGIO) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 1 Feb 2027 |
MitapivatAgios Pharmaceuticals, Inc. (AGIO) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 1 Feb 2027 |
MitapivatAgios Pharmaceuticals, Inc. (AGIO) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 12 Feb 2027 |
TinlarebantBelite Bio, Inc (BLTE) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |
| 12 Feb 2027 |
TinlarebantBelite Bio, Inc (BLTE) |
Company-disclosed PDUFA goal dateAnnounced review target |
Original source |